# Semaglutide in Schizophrenia-A Top Clinical Trial.

> PubMed lists PMID 42384388 in JAMA psychiatry as Journal Article, with publication-date metadata of 2026-07-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42384388-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42384388-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-42384388-semaglutide-v1.json
- Content SHA-256: `c99d125e626b5ef844ec74e4576cff6cd1721cecccb99747563a1a29bef85daf`

## Claims and source pins

### Headline

Semaglutide in Schizophrenia-A Top Clinical Trial. ([`pubmed-observation-pmid-42384388-2026-07-01-7625ed8753e3`](#source-pubmed-observation-pmid-42384388-2026-07-01-7625ed8753e3))

### Summary

PubMed lists PMID 42384388 in JAMA psychiatry as Journal Article, with publication-date metadata of 2026-07-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42384388-2026-07-01-7625ed8753e3`](#source-pubmed-observation-pmid-42384388-2026-07-01-7625ed8753e3))

### Paragraph 1

PubMed lists PMID 42384388 in JAMA psychiatry as Journal Article, with publication-date metadata of 2026-07-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42384388-2026-07-01-7625ed8753e3`](#source-pubmed-observation-pmid-42384388-2026-07-01-7625ed8753e3))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42384388-2026-07-01-7625ed8753e3`](#source-pubmed-observation-pmid-42384388-2026-07-01-7625ed8753e3))

## Sources

<a id="source-pubmed-observation-pmid-42384388-2026-07-01-7625ed8753e3"></a>
- **Semaglutide in Schizophrenia-A Top Clinical Trial. · retained source version 1:2026-07-01:current:7625ed8753e36bc33c47804e38a7ef996f3e33eb3b40e41716fc264f4861ef72** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42384388/) (`pubmed-observation-pmid-42384388-2026-07-01-7625ed8753e3`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Semaglutide in Schizophrenia-A Top Clinical Trial." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-42384388-semaglutide-v1.json SHA-256: c99d125e626b5ef844ec74e4576cff6cd1721cecccb99747563a1a29bef85daf.